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Available online 6 April 2016Recent studies have demonstrated that the expression of sphingosine kinase 1, the enzyme that catalyses formation
of the bioactive lipid, sphingosine 1-phosphate, is increased in lungs from patients with pulmonary arterial hyper-
tension. In addition, Sk1−/−mice are protected from hypoxic-induced pulmonary arterial hypertension. Therefore,
we assessed the effect of the sphingosine kinase 1 selective inhibitor, PF-543 and a sphingosine kinase 1/ceramide
synthase inhibitor, RB-005 on pulmonary and cardiac remodelling in amouse hypoxicmodel of pulmonary arterial
hypertension. Administration of the potent sphingosine kinase 1 inhibitor, PF-543 in amouse hypoxicmodel of pul-
monary hypertension had no effect on vascular remodelling but reduced right ventricular hypertrophy. The latter
was associated with a signiﬁcant reduction in cardiomyocyte death. The protection involves a reduction in the ex-
pression of p53 (that promotes cardiomyocyte death) and an increase in the expression of anti-oxidant nuclear fac-
tor (erythroid-derived 2)-like 2 (Nrf-2). In contrast, RB-005 lacked effects on right ventricular hypertrophy,
suggesting that sphingosine kinase 1 inhibition might be nulliﬁed by concurrent inhibition of ceramide synthase.
Therefore, our ﬁndings with PF-543 suggest an important role for sphingosine kinase 1 in the development of hy-
pertrophy in pulmonary arterial hypertension.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Sphingosine 1-phosphate (S1P) is formed by the phosphorylation of
sphingosine, catalysed by sphingosine kinase isoforms (SK1 and SK2),
which are encoded by distinct genes and differ in their subcellular
localisation, biochemical properties and functions. The S1P formed by
these enzymes can either be exported from cells (through transporter
proteins e.g. Spns2) and bind to a family of ﬁve S1P-speciﬁc G protein
coupled receptors (S1P1–5) [1,2] or can interact with speciﬁc intracellu-
lar target proteins. For instance S1P formed by nuclear SK2 inhibits
HDAC1/2 activity to induce c-fos and p21 expression [3]. Dephosphory-
lation of S1P is catalysed by S1P phosphatase and the sphingosine
formed is then acylated to ceramide, catalysed by ceramide synthase
isoforms [4]. S1P can also be irreversibly cleaved by S1P lyase to produce
(E)-2 hexedecenal and phosphoethanolamine [5].
Pulmonary arterial hypertension (PAH) is a debilitating progressive
lung disease primarily affecting small pre-capillary arteries within the
lung vasculature and is associated with vasoconstriction, vascular. This is an open access article underremodelling and pro-inﬂammatory changes. Current treatments for
PAH are targeted at improving pulmonary haemodynamics, exercise
tolerance and quality of life. Currently licenced drugs for treating PAH
are all vasodilators of three main classes: prostacyclin analogues,
endothelin receptor antagonists and phosphodiesterase 5 inhibitors.
The introduction of vasodilator therapy has markedly improved life ex-
pectancy from less than 3 years at diagnosis in the pre-treatment era to
5–7 years with current optimal combination therapy [6]. However, they
fail to halt the progressive vascular and ventricular remodelling that ul-
timately determines mortality amongst PAH patients. Hypoxia, which
induces PAH, is associated with increased expression of SK1 in human
pulmonary arterial smooth muscle cells (PASMCs) [7] and this might,
therefore, be a contributing factor to the vascular remodelling in PAH.
Indeed, SK1 expression is increased in lungs from patients with PAH
and Sk1−/− mice are protected from hypoxic-induced pulmonary hy-
pertension [8]. The S1P formed by SK1 binds to the S1P2 receptor to
promote vascular smooth muscle proliferation [8]. A variety of cardio-
vascular diseases such as PAH lead to a compensatory adaptive increase
in cardiac muscle mass e.g. hypertrophy. However, this results in dys-
functional hypertrophy which eventually progresses to right ventricular
failure (RVF), the primary cause of death in pulmonary hypertensivethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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with PAH associated RVF vary from 14–41% [9–12]. The pathophysiolog-
icalmechanisms that result in RVF are still unclear. It is well documented
that apoptosis is a key feature of left ventricular failure [13–15] and re-
cent evidence also implicates apoptosis as an important mechanism in
RVF. Serial imaging of apoptosis in right ventricular dysfunction shows
apoptosis increasing as right ventricular function declines [16] and phar-
macologically induced reductions in right ventricular hypertrophy
(RVH) are associated with reduced apoptosis [17].
Preventing apoptosis of cardiomyocytes, therefore, is a major objec-
tive for the treatment of RVH. In this regard, deletion of the Sk2 gene in
mice is associated with a considerable increase in ischaemic
reperfusion-induced injury and a reduction in the cardio-protective ef-
fect of ischaemic preconditioning [18]. These ﬁndings suggest that SK2
exerts a beneﬁcial function against heart failure. Recent studies have
also shown that S1P levels are markedly increased after myocardial in-
farction (MI) and this is associated with elevated expression of SK1
and S1P1 in the heart [19]. Moreover, inhibition of SK1 with the nM po-
tent SK1 selective inhibitor, PF-543 reduced post-MI cardiac remodel-
ling and dysfunction [19]. Indeed, inhibition of S1P lyase to increase
S1P levels enhanced cardiac remodelling and dysfunction. S1P was
shown to enhance β1-adrenergic receptor stimulation-induced pro-
inﬂammatory responses in the cardiomyocytes and FTY720 [19], a func-
tional S1P1 antagonist [20] and SK1 inhibitor [21] reduced cardiac SK1/
S1P/S1P1 signalling, ameliorated chronic cardiac inﬂammation and car-
diac remodelling and dysfunction in vivo post-MI [19].
Given the potential role of SK1 in cardiac and vascular remodelling,
we have assessed the effect of the selective nM potent SK1 inhibitor,
PF-543 on pulmonary and cardiac remodelling in a mouse hypoxic
model of PAH. PF-543 exhibits a Ki for inhibition of SK1 activity of
14 nM and inhibits SK2 by only 33% at 5 μM [22]. We have compared
PF-543 with a modestly potent inhibitor of SK1, RB-005 (IC50 =
3.6 μM for SK1 inhibition [23]), which we show here also inhibits cer-
amide synthase (CerS). Thus, the rationale for comparing PF-543 with
RB-005 is as follows. Inhibition of SK1 by PF-543 is likely to promote ac-
cumulation of sphingosinewhich can be back converted to ceramide by
ceramide synthase. Similarly, inhibition of SK1 by RB-005 is likely to in-
duce accumulation of sphingosine, but the inhibition of ceramide syn-
thase by RB-005 might be expected to prevent back conversion to
ceramide. Therefore comparative effects of PF-543 and RB-005 might
be instructive in delineating the impact of ceramide biosynthesis on
PAH.
In this study, we assessed the effect of the SK1 selective inhibitor, PF-
543 and a SK1/ceramide synthase inhibitor, RB-005 on pulmonary and
cardiac remodelling in amousehypoxicmodel of PAH. Ourﬁndings sug-
gest that SK1 might play an important role in the development of dys-
functional hypertrophy in PAH.
2. Material and methods
2.1. Animals
C57BL/6 mice were purchased from Harlan (Oxford, UK) and main-
tained at the Biological Procedure Unit, University of Strathclyde. All ex-
periments were performed under the guidelines of the UK Home Ofﬁce
Animals (Scientiﬁc Procedures) Act 1986 and were compliant with the
ARRIVE guidelines for experiments involving animals [24]. Female
mice at the age of 7–12 weeks were used in all experiments. These
were then randomly divided them into separate cages and each cage
randomly designated to a speciﬁc treatment (Cage A = PF-543, Cage
B = RB-005 and Cage C = vehicle) in a non-blinded manner.
2.2. Pharmacokinetics
2 month old female mice (C57BL/6 J) (Harlan, Oxford, UK) were
injected via the tail vein with RB-005 or PF-543 (10 or 30 mg/kg)dissolved in vehicle (20% (2-Hydroxypropyl)-β-cyclodextrin in phos-
phate buffered saline (PBS)). 20 μL blood was withdrawn via tail vein
bleeds at 15min, 30 min, 1 h, 4 h, 6 h and 24 h following drug adminis-
tration. All experiments were performed under the guidelines of the UK
HomeOfﬁceAnimals (Scientiﬁc Procedures) Act 1986 andwere compli-
ant with the ARRIVE guidelines for experiments involving animals [24].
Drug concentration was determined by MS analysis.
2.3. MS analysis
Analysis of the levels of RB-005 andPF-543 in bloodwas carried out by
using an Agilent 6460 triple quadrupole instrument (Agilent, Stockport,
UK) operated at +4 kV with a sheath gas ﬂow of 7 L/min and a gas tem-
perature of 250 °C. TheMSwas interfacedwith a 1260 inﬁnity quaternary
HPLC pump ﬁtted with an ACE C18 column (150 × 3 mm, 3 μm particle
size, HiChrom Reading UK). The mobile phase was acetonitrile/water
(50:50) containing 0.1% v/v formic acid with a ﬂow rate of 0.5 ml/min.
Chlorpromazine (20 ng) added to each blood sample as an internal stan-
dard and then an equal volume of acetonitrilewas added and proteinwas
removed by centrifugation. The following transitions were monitored in
MRMmode chlorpromazine (319→ 86, 319→ 58, collision energy (CE)
30 V), PF-543 (466 → 448, 466 → 223, CE 30 V), RB-005 (318 → 217,
318→ 119 CE 30 V). Calibration curves were constructed by adding stan-
dards in the range 0–200 ng to blood samples from non-treated animals.
Plotting the ratio of internal standard response over responses for the
analytes resulted in calibration curves with R2 N 0.99.
2.4. Hypoxic induced PAH
Mice were placed into a hypobaric chamber and maintained at
550 mbar atmospheric pressure (~10% O2 concentration) for a period
of 3 weeks. Every second daymice received an intraperitoneal injection
of RB-005, PF-543 (10mg/kg and 1mg/kg, respectively) or vehicle (20%
(2-Hydroxypropyl)-β-cyclodextrin in PBS). The chamber was
depressurized and then repressurised in order to inject the mice [25].
2.5. Measurement of right ventricular pressure
Anaesthesia of mice was induced by 3% isoﬂurane in O2 and body
weight measured. Anaesthesia was maintained by 1–2% isoﬂurane in
O2 supplied via a face mask. Right ventricular pressure (RVP) was
measured by transdiaphragmatic cardiac puncture utilizing a 25G
hypodermic needle attached to a ﬂuid ﬁlled pressure transducer
(ADinstruments, Oxford, UK) which was advanced through the dia-
phragm and into the right ventricle. Mice were euthanized by cervical
dislocation and the heart and lungs dissected for subsequent analysis.
2.6. Measurement of right ventricular hypertrophy
Atria and large calibre blood vessels were dissected from the rest of
the heart. The right ventricle (RV) free wall was then dissected away
from the left ventricle (LV) and septum (S). The LV + S along with the
RV were blotted dry and weighed separately. The ratio of RV/(LV + S)
was used as an index of RVH.
2.7. Assessment of vascular remodelling
Sagittal sections from the right lung (5 μm)were ﬁxed, parafﬁn em-
bedded and stained with Elastica-Van Gieson stain (Merck Millipore,
Nottingham, UK) before being microscopically assessed for evidence
of muscularisation of small pulmonary arteries (b80 μm diameter).
Arteries were considered muscularised if they possessed a distinct
double-elastic lamina visible aroundat least 70% of the vessel circumfer-
ence. At least 150 vessels per section were counted. The percentage of
muscularised (remodelled) vessels was calculated as the number of
remodelled vessels / total number of vessels counted × 100.
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Right ventricular tissue sections (5 μm)were ﬁxed, parafﬁn embed-
ded and DNA strand breaks detected by a Terminal deoxynucleotidyl
transferase (TdT) dUTP Nick-End Labelling (TUNEL) assay kit (Roche,
Burgess Hill, UK) according to the manufacturer's instructions. Sections
were then counterstained with haematoxylin and apoptotic cells were
automatically counted using ImageJ (NIH) software. At least 400 cellsFig. 1. Effect of PF-543 and RB-005 on body weight, blood concentration, SK1 activity and expre
(A) Pharmacokinetics of RB-005 (10 and 30 mg/kg) and PF-543 (10 and 30 mg/kg) during 24
hypoxia (for 21 days) in the presence and absence of RB-005 (10 mg/kg) or PF-543 (1 mg/kg
PF-543 and RB-005 is shown. (B) Western blot of biomarkers in pulmonary vessels from mic
(for 21 days) in the presence and absence of RB-005 (10 mg/kg) (Right panels). Actin was
arteries pooled from 4 mice, representative of 2 independent experiments. Hypoxic study blot
experiments. (C) Effect of PF-543 or RB-005 on CerS5 activity (activity (pmol/min/mg prote
effect of PF-543 or RB-005 on SK1 expression in cultured PASMC (24 h treatment). Actin w
independent experiments. (D) Effect of PF-543 or RB-005 on caspase 3/7 activity in cultured
inhibitor) was used as a positive control. Results are expressed as mean caspase 3/7 activity ±were counted per heart and apoptotic index calculated as number of ap-
optotic cells / total number of cells counted × 100.
2.9. Cell culture
Human PASMC were grown in human smooth muscle cell growth
medium supplemented with growth supplement, 100 U/mL penicillin
and 100 μg/mL streptomycin at 37 °C in 5% CO2.ssion in pulmonary arteries and cultured human pulmonary arterial smooth muscle cells.
h treatment with these compounds. Also shown is the body weight of mice exposed to
). n = 4–6 mice/group (results are expressed as mean ± SD). The chemical structure of
e exposed to RB-005 (10 mg/kg) or PF-543 (10 mg/kg) for 24 h (left panels) or hypoxia
used as a protein loading control. Blots from acute (24 h) treatments are of pulmonary
s display pulmonary arteries pooled from 4 animals, representative of 2 or 3 independent
in) expressed as % of control and is mean ± SD, n = 3) and western blot showing the
as used as a protein loading control. Western blot results are representative of three
human pulmonary arterial smooth muscle cells (24 h treatment). MG132 (proteasomal
SD for n = 3 experiments. *** p b 0.001 versus control.
Fig. 1 (continued).
Fig. 2. Effect of PF-543 and RB-005 on RVP and vascular remodelling. Effect of RB-005
(10 mg/kg) or PF-543 (1 mg/kg) on (A) RVP (vehicle n = 7–8 mice, RB-005 n = 3–5
mice/group; PF-543, n = 3–4 mice/group, ** p b 0.01, *** p b 0.001 versus normoxic) and
(B) vascular remodelling (n = 4–6 mice per group, *** p b 0.001 versus normoxic; +
p b 0.01 versus hypoxic vehicle; # p b 0.05 versus PF-543/hypoxic).
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PASMC extracts for SDS-PAGE and Western blot analysis were pre-
pared by washing treated cells with 5 ml of PBS and then re-
suspending cell pellets in whole cell lysis buffer [(137 mM NaCl,
2.7 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1% v/v NP40, 10% v/v glycerol,
20 mM Tris) (pH 8.0) containing 0.2 mM PMSF, 10 μg/mL leupeptin,
10 μg/mL aprotinin, 0.5 mM Na3VO4, 100 μM NaF, and 10 mM β-
glycerophosphate]. Samples were repeatedly (×6) passed through a
23 gauge needle using a syringe and rotated for 60 min at 4 °C to
allow for efﬁcient lysis. Cell debris was pelleted by centrifugation at
22,000 g for 10 min at 4 °C and the supernatant (whole cell extract)
was collected. Right ventricular tissue was placed into modiﬁed RIPA
buffer [(50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS) (pH 7.5) containing 0.2 mM PMSF,
10 μg/mL leupeptin, 10 μg/mL aprotinin, 0.5 mM Na3VO4, 100 μM NaF,
and 10 mM β-glycerophosphate] before being pulverized using a liquid
N2 cooledmortar and pestlemaintained on dry ice. Sampleswere rotat-
ed for 60 min at 4 °C before being centrifuged at 22,000 g for 10 min at4 °C. Supernatants were then collected. The protein content of PASMCs
and ventricular lysates was measured using the Pierce BCA Assay Kit
(Fisher Scientiﬁc UK, Loughborough). For each sample, 10–20 μg of pro-
tein, combinedwith Lamelli buffer [(0.5 mMTris, 2 mMNa4P2O7, 5 mM
EDTA, 2% w/v SDS) (pH 6.7) containing 12.5% v/v glycerol, 0.25% w/v
bromophenol blue, and 50 mM dithiothreitol] was used for SDS-PAGE
andWestern blotting. Proteins were separated on a 10% (v/v) acrylam-
ide/bisacrylamide gel, and transferred to a nitrocellulose Hybondmem-
brane (GE Healthcare, Little Chalfont, UK). Membranes were blocked in
5% (w/v) bovine serum albumin (BSA) (Fisher Scientiﬁc UK, Loughbor-
ough) in TBST buffer (20 mM Tris HCl (pH 7.5), 48 mMNaCl, 0.1% (v/v)
Tween20) for 1 h at room temperature prior to incubationwith primary
antibody (diluted in blocking buffer) overnight at 4 °C. Following three
washes in TBST, membranes were incubated with horse radish
peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary anti-
body (Sigma, Poole, UK; diluted in blocking buffer), as appropriate, for
1 h at room temperature. Immunoreactive protein bands were visual-
ized using enhanced chemiluminescence. Primary antibodies were
sourced as follows: phospho-p38 MAPK (#9211), phospho-ERK2
(#9101), phospho-STAT3 (#9131), ERK2 (#9108), PARP (#2965)
from Cell Signalling Technologies (NEB, Hitchin, UK), PCNA (sc-56)
and Nrf2 (sc-13032) from Santa Cruz (Insight Biotechnology,Wembley,
UK), actin (A2547), p53 (P8999) and ﬁbronectin (F3648) from Sigma
(Poole, UK). Anti-SK1 (lab reference number 48:2) antibody was cus-
tom made by Abcam using antigens detailed in [26].
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Right ventricular homogenate was incubated for 60 min at 30 °C, in
the presence of 3 μM sphingosine, 250 μM [γ-32P]ATP (37 kBq) in
20 mM Tris (pH 7.4), 1 mM EDTA, 1 mM Na3VO4, 40 mM β-
glycerophosphate, 1 mM NaF and 500 μMMgCl2 in the presence of Tri-
ton X-100 (~0.6% v/v). Assay reactionswere terminated by the addition
of 500 μL of 1-butanol. After 1 mL of 2 M KCl was added, with mixing,
two phases were formed. The lower (aqueous) phase, which contains
unreacted [γ-32P]ATP, was removed and discarded. The organic phase
containing [32P]-S1P was extracted by washing twice with 2 M KCl
(1 mL each time) before quantiﬁcation by Cerenkov counting.
2.12. CerS assay
Cell homogenates fromHEK 293 cells overexpressing CerS5were in-
cubated at 37 °C with 15 μM NBD-Sph (Avanti Polar Lipids, Alabaster,
USA), 20 μMdefatted BSA and 50 μMacyl CoA in a 20 μl reaction volume
according to Tidhar et al., [27] Reactions were terminated by the addi-
tion of chloroform/methanol (1:2, v/v) and lipids were extracted. Lipids
were then dried underN2, resuspended in chloroform/methanol (9:1, v/
v) and separated by TLC using chloroform/methanol/2 M NH4OH
(40:10:1, v/v/v) as the developing solvent. NBD-labelled lipids were vi-
sualized using a Typhoon 9410 variable mode imager and quantiﬁed by
ImageQuantTL (GE Healthcare, Chalfont St Giles, UK).
2.13. Caspase-3/7 assay
PASMCs (10,000 per well) were seeded into white walled 96 well
plates and allowed to adhere for 24 h. Subsequently, media was
replenished with 100 μL of media containing either PF-543 (100 nMFig. 3. Representative photomicrographs of pulmonary vascular remodelling. Effect of RB-005 (
mice/group. Scale bar represents 100 μm. Black arrows indicate non-remodelled vessels whileor 1 μM), RB-005 (1 or 10 μM), vehicle control or positive control
(proteasomal inhibitor, MG132; 10 μM) and incubated for a further 2
to 4 h. Caspase-Glo® 3/7 Reagent (Promega, Southampton, UK) was
prepared according to the manufacturer's instructions and 100 μL was
added to each well and incubated at room temperature for 2 h before
reading on a luminometer. Following caspase cleavage, a substrate for
luciferase (aminoluciferin) is released, resulting in the luciferase
reaction and the production of light. The luminescent signal intensity
produced is proportional to the amount of caspase 3/7 activity. Lumi-
nescent signal was acquired using a Wallac Victor plate reader (Perkin
Elmer Seer Green, UK).
3. Results and discussion
3.1. Effect of PF-543 and RB-005 on body weight, blood concentration, SK1
activity and expression in pulmonary arteries and cultured human
pulmonary arterial smooth muscle cells
Mice were initially dosed (ip) with 10 mg/kg or 30 mg/kg of PF-543
for 24 h and the T0.5 was 1.2 h in blood samples (Fig. 1A). We have pre-
viously shown that SK1 inhibitors can bind to SK1 to induce the
proteasomal degradation of SK1 [22,23] and this is a biomarker for tar-
get engagement. Indeed, administration of 10 mg/kg PF-543 for 24 h to
mice induced a decrease in SK1 expression in pulmonary vessels
(Fig. 1B). Moreover, treatment of cultured PASMC with PF-543 for
24 h abolished SK1 expression at nM concentrations which correlates
with the Ki for inhibition of SK1 activity (Fig. 1C, [22]), indicating that
in vivo effects of PF-543 are recapitulated in an in vitro pulmonary arte-
rial smooth muscle cell model.
We calculated that 10 mg/kg ip dosing of PF-543 yields an initial
blood concentration of 50 μg/mL blood, which corresponds to10mg/kg) or PF-543 (1mg/kg) on vascular remodelling. Images are representative of 4–6
white arrows indicate remodelled vessels.
Fig. 4. Effect of PF-543 and RB-005 on right ventricular hypertrophy. (A) Effect of RB-005
(10mg/kg) or PF-543 (1mg/kg) on right ventricular hypertrophy (n= 4–10mice/group,
* p b 0.05, *** p b 0.001 versus normoxic; + p b 0.05 versus vehicle/hypoxic). (B)Western
blot of PARP processing in right ventricles of mice exposed to normoxia or hypoxia and
vehicle or PF-543 (1 mg/kg) for 21 days. ERK-2 was used as a protein loading control.
Results are representative of n = 6 mice/group (each lane corresponds to a separate
animal). (C) Right ventricular SK1 activity. Results are expressed as mean activity
(pmol/min/μg protein) ± SD (n = 3 mice). (D) Images of TUNEL staining in right
ventricles from hypoxic and PF-543/hypoxic treated mice (3 mice/group) with
quantiﬁcation of apoptotic index. DNase was used as a positive control. Scale bar
represents 50 μm. Black arrows indicate negative TUNEL staining of cardiomyoctes,
while white arrows indicate positive TUNEL (brown colour) staining of cardiomyocytes.
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chronic exposure experiments, a dose that has previously been shown
to be sufﬁcient for SK1 inhibition and reduction of serum and cardiac
S1P levels in mice [19]. Chronic hypoxia prevented weight gain but
PF-543 had no effect over hypoxia (Fig. 1A).We also used the SK1 selec-
tive inhibitor, RB-005 [23]. In contrast with PF-543, RB-005 is also an in-
hibitor of ceramide synthase (Fig. 1C). This has allowed us to investigate
the effect of modulating ceramide biosynthesis in regulating vascular
remodelling in the hypoxic PAH model. The IC50 for inhibition of SK1
is 3.6 μM [23] and for ceramide synthase 5 it was ~20 μM (Fig. 1C).
RB-005 is an FTY720 analogue and indeed, FTY720 has also been
shown to also inhibit ceramide synthase; dependent on the chain length
of the acyl CoA substrate [28]. Paradoxically, FYT720 increased ceramide
levels in HEK cells [28], which might be due to either kinetic consider-
ations [28] and/or due to the fact that FTY720 is also an inhibitor of
SK1 [21].
At 10 mg/kg or 30 mg/kg of RB-005, the T0.5 was 2.1 h in blood sam-
ples (Fig. 1A). There was no adverse effect on body weight in animals
chronically dosed with RB-005 for 21 days (Fig. 1A). Administration of
RB-005 (10 mg/kg) (which corresponds to ~30 μM initially, assuming
100% bioavailability) in vivo for 24 h also reduced SK1 expression in pul-
monary vessels under normoxic conditions (Fig. 1B). This was con-
ﬁrmed using cultured PASMC where RB-005 reduced SK1 expression
(Fig. 1C, [23]). Administration of RB-005 (10 mg/kg) to mice for
21 days reduced SK1 expression in vivo in pulmonary vessels from
mice maintained under normoxic conditions, but had no effect under
hypoxic conditions (Fig. 1B). The failure of RB-005 to reduce SK1 ex-
pression in blood vessels under hypoxic conditionsmight suggest resis-
tance of SK1 to proteasomal degradation. Indeed, a similar resistance to
SK1 inhibitors has been observed in certain cancer cells [29]. Themech-
anism is unknown but suggests that a possible hypoxic-dependent
post-translational modiﬁcation of SK1might increase its stability in vivo.
RB-005 induced an increase in PARP cleavage and the phosphoryla-
tion of ERK-1/2 and p38 MAPK in vessels from mice maintained under
normoxic conditions suggesting that this inhibitor might promote vas-
cular injury itself (Fig.1B). These responses were absent or diminished
after exposure to chronic hypoxia (Fig. 1B). PCNA expression was also
increased by RB-005 under both normoxic and hypoxic conditions
(Fig. 1B). RB-005 (10 μM) exhibits a differentmechanism of action com-
paredwith PF-543, as it induced caspase-3/7 activity in cultured human
pulmonary smooth muscle cells (Fig. 1D). These ﬁndings suggest that
inhibition of ceramide synthase and SK1 activity might be the most ef-
fective means of inducing apoptosis of human pulmonary smoothmus-
cle cells in vitro under normoxic conditions.
3.2. Effect of RB-005 or PF-543 on right ventricular pressure and pulmonary
vascular remodelling
Mice subjected to 21 days of hypoxia exhibited a marked increase in
mean right ventricular pressure (RVP) compared to normoxic controls
(Fig. 2A) and this was associated with a signiﬁcant increase in vascular
remodelling (Fig. 2B). We noted that hypoxia did not increase phos-
phorylated ERK-1/2 levels in the arteries (Fig. 1B). The effect of hypoxia
on PASMC proliferation is controversial, particularly under cell culture
conditions with both growth promoting and suppressing phenotypes
being observed [30]. In whole artery preparations, such as those used
here, the dominant cell type proliferating under hypoxic conditions is
likely to be pulmonary artery ﬁbroblasts rather than PASMCs (which
undergo hypertrophy rather than hyperplasia) which proliferate in an
ERK1/2 independent manner [31].
Administration of 1 mg/kg PF-543 or 10 mg/kg RB-005 at the onset
of hypoxia had no effect onmeanRVP (Fig. 2A).While PF-543 had no ef-
fect (Figs. 2B, 3), RB-005modestly enhanced hypoxia-dependent vascu-
lar remodelling (Figs. 2B, 3). This enhancement was evident in terms of
absolute number of remodelled vessels and also inmore extensive elas-
tin staining. These ﬁndings are associated with a failure of RB-005 toreduce SK1 expression in vessels from mice treated with hypoxia for
21 days (Fig. 1B) and an RB-005-dependent increase in the level of
phosphorylated ERK-1/2 and p38 MAPK, which could contribute to a
proliferative response. Most signiﬁcantly, RB-005 failed to induce
PARP cleavage in vessels from mice that had been subjected to hypoxia
for 21 days (Fig. 1B) and this might reﬂect a reduced apoptotic rate that
could account for the increase in vascular remodelling in response to
RB-005. This is also consistent with the possibility that the inhibition
of ceramide synthase by RB-005 might reduce the formation of apopto-
tic ceramide.
Fig. 4 (continued).
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Interestingly, PF-543 but not RB-005 signiﬁcantly reduced right ven-
tricular hypertrophy (RVH) (Fig. 4A). It is frequently assumed that in-
creased RVH is subsequent to and correlates with elevated RVP yet
data from animal models has cast doubt on this assumption with
sustained RVP existing in the absence of signiﬁcant RVH [31]. Conversely,
RVH has been observed to develop in mice lacking peripheral serotonin
following chronic exposure to hypoxia despite RVP remaining normal
[32]. This is suggestive of a direct effect of hypoxia on cardiac hypertro-
phic signalling pathways. Therefore, our ﬁndings with PF-543 do not
support a major protective function of SK1 on vascular remodelling,
but instead invoke a direct role in cardiac dysfunctional hypertrophy.
The failure of the SK1 inhibitor, PF-543, to reduce vascular remodelling
contrasts with ﬁnding that Sk1−/− mice are protected from hypoxic-
induced pulmonary hypertension [8]. However, PF-543 administration
is for 21 days and does not reﬂect the same chronic system in which
the Sk1 gene is deleted. In addition, SK2 might compensate for the loss
of SK1 in Sk1 knockout mice and this is clearly evident from the ﬁnding
that Sk1 or Sk2 knockout mice survive, while dual Sk1/Sk2 knockoutmice do not survive, suggesting some redundancy in the function of
the two kinases [33,34]. Chen et al., [8] have also demonstrated a protec-
tive effect of the dual SK1/SK2 inhibitor, SKi (2-(p-hydroxyanilino)-4-(p-
chlorophenyl)thiazole). However, SKi also inhibits dihydroceramide
desaturase [35] and the effect on vascular remodelling is unknown.
To establish the mechanism by which PF-543 is protective against
RVH, we measured the expression level of several proteins that are
known to be involved in the development of hypertrophy. First, we
found that neither hypoxia nor PF-543 had any effect on right ventricular
SK1 expression (Fig. 4B) or SK1 activity (Fig. 4C). The results concerning
SK1 activity conﬁrm thewestern blot analysis which showed no changes
in SK1 expression in response to PF-543 in right ventricle homogenates.
We also found that hypoxia induces the appearance of ADP-ribosylated
PARP (Mr N 120 kDa) in the right ventricular tissue and this is completely
blocked by administration of PF-543 to mice (Fig. 4B). ADP ribosylation
of PARP is an early step involved in its proteolytic degradation preceding
apoptosis [36]. We therefore used TUNEL staining (to detect double
stranded DNA nicks that are a marker of apoptosis/necrosis) on right
ventricular sections. Signiﬁcant positive TUNEL staining was observed
in the right ventricular sections from hypoxic treated mice (Fig. 4D),
Fig. 5. Effect of PF-543 and RB-005 on biomarkers in right ventricular hypertrophy.Western blot of biomarkers (A) p53, Nrf-2, SK1, ﬁbronectin (results are representative of 3–5mice and
each lane corresponds to a separate animal); (B) P-STAT3 (results are representative from n=2mice/group and each lane corresponds to a separate animal) in right ventricles frommice
exposed to RB-005 (10 mg/kg) or PF-543 (1 mg/kg) under normoxic or hypoxia (21 days) conditions. ERK-2 was used as a protein loading control.
Fig. 6. Summary of the effects of PF-543 and RB-005 on RVP, vascular remodelling and right ventricular hypertrophy in a hypoxia treatedmousemodel. Schematic shows that SK1 inhibitor, PF-
543 reduces right ventricular hypertrophywithout affecting vascular remodelling and RVP under hypoxic conditions. This is due to protection against cardiomyocyte apoptosis and is associated
with a reduction in p53 expression and an increase in anti-oxidant Nrf-2 expression. In contrast, RB-005, which inhibits both ceramide synthase and SK1 has no effect on right ventricular
hypertrophy or RVP and slightly increased vascular remodelling under hypoxic conditions suggesting that inhibition of ceramide synthase might negate the effect of inhibiting SK1 in PAH.
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hypoxia and suggesting deleterious progression of right ventricular phe-
notype. Administration of PF-543 (1 mg/kg) to the mice caused a ~ 50%
reduction in TUNEL staining (Fig. 4D) indicative of signiﬁcant protection
against apoptosis/necrosis and consistent with the reduction in RVH.
3.4. Effect of PF-543 on signalling biomarkers of hypertrophy
The protection afforded by PF-543 (1 mg/kg) in preventing cardio-
myocyte apoptosis/necrosis in right ventricles of mice exposed to hyp-
oxia involves a reduction in the expression of p53 (that promotes
cardiomyocyte death) (Fig. 5A) and an increase in the expression of
an anti-oxidant protein, nuclear factor (erythroid-derived 2)-like 2
(Nrf-2) (Fig. 5A). Nrf-2 is a potentially key molecule in preserving
right ventricular function, which might be up-regulated in an attempt
to limit damage to the RV. Indeed, a detailed investigation of the RV in
rats subjected to a severe angioproliferative model of PAH that results
in RV failure revealed RV ﬁbrosis, capillary loss and cardiomyocyte apo-
ptosis, which could be partially reversed with Nrf-2 antioxidant treat-
ment suggesting oxidative damage may contribute to the failing RV
[37]. PF-543 (1 mg/kg) had no effect on ﬁbronectin expression
(Fig. 5A) indicating that ﬁbrosis is not affected in early stage PAH. Inter-
estingly, PF-543 increasedp53 expression andhadnoeffect onNrf-2 ex-
pression under normoxic conditions (Fig. 5A), suggesting that its effect
on hypertrophy under hypoxic conditions involves targeting the
hypoxic-dependent and disease-forming mechanism. RB-005
(10 mg/kg) had no effect on the hypoxic-dependent regulation of p53,
Nrf-2 or ﬁbronectin either under hypoxic or normoxic conditions
(Fig. 5A).
Cardiac SK1/S1P/S1P1 signalling has recently been shown to pro-
mote chronic cardiac inﬂammation and cardiac remodelling and dys-
function post-MI [19]. In this regard, PF-543 (1 mg/kg) administration
to mice caused a reduction in phosphorylated STAT3 levels in the right
ventricles from both normoxic and hypoxic mice. While RB-005
(10 mg/kg) reduced STAT3 phosphorylation under normoxic condi-
tions, it had a less marked effect (and might conceivably stimulate
STAT3 phosphorylation) under hypoxic conditions (Fig. 5B). Hypoxia
also reduced STAT3phosphorylation levels (Fig. 5B). Theseﬁndings sug-
gest that the changes observedwith PF-543 on hypertrophy are not spe-
ciﬁc to the hypoxic-dependent changes in the STAT3 inﬂammatory
pathway. Therefore, we did not ﬁnd support for the model proposed
by Zhang et al., [19], at least in the PAH model.
4. Conclusion
We have identiﬁed a compound, PF-543 (a potent sphingosine ki-
nase 1 inhibitor) which has a dramatic effect on hypertrophic-induced
myocardial apoptosis, which is the major killer in humans suffering
from PAH. The ﬁndings of the current study demonstrate that PF-543
failed to reduce vascular remodelling. However, PF-543 did reduce
dysfunctional hypertrophy, associated with protection against cardio-
myocyte apoptosis (Fig. 6). This protection against cardiomyocyte apo-
ptosis occurs as the development of dysfunctional hypertrophy is
reduced and therefore fewer cardiomyocytes reach the stage where
they are prone to apoptosis. These effects are not recapitulated by RB-
005, suggesting that inhibition of ceramide synthase negates the bene-
ﬁcial effects of inhibiting SK1 activity on hypertrophy in PAH (Fig. 6).
Therefore, it will be necessary to produce compounds that lack inhibito-
ry activity against ceramide synthase (active in both the de novo cer-
amide synthesis pathway and also in the sphingolipid rheostat) in
order to execute the effect of inhibiting SK1 on hypertrophy in PAH.
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